Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, […]
Total raised: $11M
Investors 1
| Date | Name | Website |
| - | Dolby Fami... | dolbyventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.08.2017 | Series A | $11M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 02.04.2019 | 10+ can't-miss Houston business and innovation events for Ap... | Happy Q2, everyone. With 2019 already a quarter of the way through, it's a bit overwhelming to prior... | houston.in... |
| 19.08.2017 | Four intriguing biopharma developments this week | Alzeca Biosciences in Houston closed an $11 million Series A round to advance an imaging technology ... | medcitynew... |
| 18.08.2017 | Alzeca Biosciences Closes $11 Million Series A Financing | - | dolbyventu... |
| 17.08.2017 | Alzeca Biosciences Closes $11M Series A Financing | Alzeca Biosciences, Inc., a Houston-based early-stage healthcare diagnostic company focused on devel... | finsmes.co... |
| - | Four intriguing biopharma developments this week | Even in the dog days of summer, it was hardly a dull week in the world of biopharma. Amidst the fall... | medcitynew... |